Of note, our studies17 and those of others51–53 have demonstrated that SREBP-1c upregulates PCSK9 expression and induces lipogenesis-associated genes, which are believed to accelerate NAFLD pathogenesis. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.